MICHAEL E. PREVOZNIK - 26 Sep 2025 Form 4 Insider Report for QUEST DIAGNOSTICS INC (DGX)

Role
SVP & General Counsel
Signature
Sean D. Mersten, Attorney in Fact for Michael E. Prevoznik
Issuer symbol
DGX
Transactions as of
26 Sep 2025
Transactions value $
-$42,706
Form type
4
Filing time
30 Sep 2025, 16:36:58 UTC
Previous filing
25 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
PREVOZNIK MICHAEL E SVP & General Counsel 500 PLAZA DRIVE, SECAUCUS Sean D. Mersten, Attorney in Fact for Michael E. Prevoznik 30 Sep 2025 0001222679

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DGX Common Stock Options Exercise $23.5K +227 +0.6% $103.57 38.3K 26 Sep 2025 Direct F1
transaction DGX Common Stock Sale -$15.5K -83 -0.22% $187.22 38.3K 26 Sep 2025 Direct F1, F2
transaction DGX Common Stock Sale -$27.2K -144 -0.38% $188.66 38.1K 26 Sep 2025 Direct F1, F3
holding DGX Common Stock 5.69K 26 Sep 2025 401(k)/SDCP F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DGX Non-Qualifed Stock Option (right to buy) Options Exercise -$23.5K -227 -100% $103.57 0 26 Sep 2025 Common Stock 227 $103.57 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
F2 This transaction was executed in multiple trades at prices ranging from $187.00 to $187.480. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 This transaction was executed in multiple trades at prices ranging from $188.220 to $189.080. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.
F5 The options vested in three annual installments beginning with the first on February 19, 2019, the second on February 19, 2020 and the final on February 19, 2021.